Company Encyclopedia
View More
name
LEADS BIOLABS-B
09887.HK
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody.
1.294 T
09887.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LEADS BIOLABS-B: One LBL-034 clinical study selected for the first oral presentation on the first day of the 67th ASH Annual Meeting

    LEADS BIOLABS-B announced that its research summary has been selected for presentation at the 67th American Society of Hematology Annual Meeting. Among them, the clinical study of LBL-034 will have its first oral presentation on the first day of the conference, focusing on its efficacy and safety data for patients with relapsed/refractory multiple myeloma

    Zhitong·
    HK
    09887
    -1.39%
    Zhitong·
    HK
    09887
    -1.39%

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%, while RemeGen, JUNSHI BIO, and WuXi BIO all declined

    Zhitong·
    SH
    688180
    -1.41%
    HK
    01877
    -0.60%
    US
    WXXWY
    +3.94%
    Zhitong·
    SH
    688180
    -1.41%
    HK
    01877
    -0.60%
    US
    WXXWY
    +3.94%

    LEADS BIOLABS-B: LBL-024 administered to the first patient in the Phase II trial for the treatment of biliary tract cancer

    LEADS BIOLABS-B announced that the PD-L1/4-1BB bispecific antibody LBL-024 has successfully treated the first patient in a Phase II clinical trial for frontline treatment of biliary tract cancer, marking progress in the expansion of the product's indications. The trial is led by Zhongshan Hospital affiliated with Fudan University and aims to evaluate the efficacy and safety of LBL-024 in combination therapy for patients with advanced biliary tract cancer. LBL-024 is expected to become the first approved drug for the treatment of advanced pulmonary neuroendocrine carcinoma

    Zhitong·
    HK
    09887
    -1.39%
    Zhitong·
    HK
    09887
    -1.39%

    LEADS BIOLABS-B signs a global exclusive licensing agreement with DIANTHUS for LBL-047

    LEADS BIOLABS-B has signed a global exclusive licensing agreement with Dianthus Therapeutics, Inc. to collaborate on the development of the anti-BDCA2-TACI bispecific fusion protein LBL-047. Dianthus will obtain the research, production, and commercialization rights for LBL-047 outside of Greater China, while LEADS BIOLABS-B will receive an upfront payment of up to $38 million and potential milestone payments of $1 billion, as well as the right to receive tiered royalties outside of Greater China. This agreement will strengthen the company's commitment to innovative drug development

    Zhitong·
    HK
    09887
    -1.39%
    Zhitong·
    HK
    09887
    -1.39%

    LEADS BIOLABS-B: Results of 2 innovative drug research projects will be presented at the 67th ASH Annual Meeting

    LEADS BIOLABS-B announced that the research results of its two innovative drugs will be presented at the 67th ASH Annual Meeting, including one oral presentation, three poster presentations, and one online publication. The selection of these research results demonstrates the international academic community's recognition of the company's scientific research innovation capabilities

    Zhitong·
    HK
    09887
    -1.39%
    Zhitong·
    HK
    09887
    -1.39%
    Posts
    View More

    $LEADS BIOLABS-B(09887.HK) got 3 lots and sold 2 lots, thanks to Longbridge and the new stock.

    • 0

    $LEADS BIOLABS-B(09887.HK) Let's go all in $DUALITYBIO-B(09606.HK) hoping to replicate the trend.

    • 0
    © 2025 Longbridge｜Disclaimer